Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply

Natural Killer T Cell Function in Lymphoma Patients.

Biomolecules·2026

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.

Haematologica·2021

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.

Leukemia & lymphoma·2021

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.

International journal of hematology·2021

Emerging treatment strategies for COVID-19 infection.

Clinical and experimental medicine·2020

A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

American journal of hematology·2020

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

The Lancet. Oncology·2026

Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2026

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

The Lancet. Oncology·2026

Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

The Lancet. Oncology·2026

Cordycepin Alleviates Non Alcoholic Fatty Liver Disease Progression by Stabilizing GCH1 to Inhibit Ferroptosis.

Phytotherapy research : PTR·2026

Utility of 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in assessing treatment response after chemoradiotherapy for cervical cancer.

Journal of radiation research·2026

Multidimensional Exploration of Platinum Complexes for Cancer Therapy.

Angewandte Chemie (International ed. in English)·2026

Electroacupuncture for Postoperative Gastrointestinal Recovery After Laparoscopic Colorectal Cancer Resection: A Randomized Controlled Trial Electroacupuncture Fastens Recovery.

Diseases of the colon and rectum·2026

Updates in systemic therapy for refractory thyroid carcinoma - targeted agents, immunotherapy, and chemotherapy.

Current opinion in endocrinology, diabetes, and obesity·2026

Stereotactic Radiosurgery for Malignant Melanotic Nerve Sheath Tumors: A Case Series.

Cureus·2026

Related Experiment Videos

Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply

Related Concept Videos

Natural Killer T Cell Function in Lymphoma Patients.

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.

Emerging treatment strategies for COVID-19 infection.

A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

Cordycepin Alleviates Non Alcoholic Fatty Liver Disease Progression by Stabilizing GCH1 to Inhibit Ferroptosis.

Utility of 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in assessing treatment response after chemoradiotherapy for cervical cancer.

Multidimensional Exploration of Platinum Complexes for Cancer Therapy.

Electroacupuncture for Postoperative Gastrointestinal Recovery After Laparoscopic Colorectal Cancer Resection: A Randomized Controlled Trial Electroacupuncture Fastens Recovery.

Updates in systemic therapy for refractory thyroid carcinoma - targeted agents, immunotherapy, and chemotherapy.

Stereotactic Radiosurgery for Malignant Melanotic Nerve Sheath Tumors: A Case Series.

Related Experiment Videos

Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply

Related Concept Videos

Related Articles